UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
September
2025
Commission
File Number: 001-38723
Tiziana
Life Sciences LTD
(Exact
Name of Registrant as Specified in Its Charter)
9th Floor
107
Cheapside
London
EC2V
6DN
(Address
of registrant’s principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On September 24, 2025, Tiziana Life Sciences LTD (the “Company”)
issued this 6K announcing that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research
of Multiple Sclerosis (ECTRIMS), being held September 24-26, 2025, in Barcelona, Spain. The ECTRIMS Congress is the world’s largest
annual international conference dedicated to basic and clinical research in multiple sclerosis. It brings together leading scientists,
clinicians, and industry partners to share the latest advances in MS research and treatment.
The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
TIZIANA LIFE SCIENCES LTD |
| |
|
|
|
| Date: September 24, 2025 |
By: |
/s/ Keeren Shah |
| |
|
Name: |
Keeren Shah |
| |
|
Title: |
Chief Financial Officer |
EXHIBIT INDEX
| Exhibit No. |
|
Description |
| |
|
|
| 99.1 |
|
Tiziana Life Sciences LTD Press Release, dated September 24, 2025 |
